VJOncology is committed to improving our service to you

ESMO Breast 2020 | HER2-E pCR with anti-HER2-based neoadjuvant therapies

VJOncology is committed to improving our service to you

Aleix Prat

Aleix Prat, MD, PhD, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain, discusses a meta-analysis that validated the association of the HER2-E subtype with pathological complete response (pCR) following anti-HER2-based neoadjuvant treatments with or without chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter